Ted W. Love, MD

Ted served as President and Chief Executive Officer of Global Blood Therapeutics (GBT) as well as a member of its board from June 2014 to October 2022. Previously, he was Executive Vice President, Research and Development and Technical Operations, at Onyx Pharmaceuticals, Inc. Prior to Onyx, Ted served as President, Chief Executive Officer and Chairman of Nuvelo, Inc. Prior to Nuvelo, he served as Senior Vice President, Development, at Theravance, Inc. Earlier in his career, Ted held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and Vice President, Product Development. At Genentech, Ted oversaw the development strategy and execution resulting in approvals of leading therapies such as Rituxan®, Herceptin®, Xolair® and Avastin®. Dr. Love serves on the board of directors of Seagen, Inc. and he previously served on the board of directors of Amicus Therapeutics, Inc., a biotechnology company, and Cascadian Therapeutics, Inc., a biopharmaceutical company.

Ted holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.

Stay up to date

Subscribe to Royalty Pharma news and alerts